Zephyrus Innovations appoints David Whitaker as Chief Technology Officer
Vancouver, Canada – 30 May 2023: Zephyrus Innovations (Zephyrus),…
30 May 2023/by Healthcare TeamAdcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline
Strengthening of strategic option license agreement to cover…
30 May 2023/by Healthcare TeamDestiny Pharma plc – Dr Debra Barker Appointed Interim CEO
Brighton, United Kingdom – 25th May 2023: Destiny Pharma…
25 May 2023/by Healthcare TeamWe’d love to hear from you
For more information about optimum Strategic Communications, please get in touch
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
/in Client newsiOnctura To Present Research At Leading Scientific Conferences In June 2023
/in Client newsAriceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
/in Client newsZephyrus Innovations appoints David Whitaker as Chief Technology Officer
/in Client newsAdcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline
/in Client news